Published in Protein Sci on March 01, 2010
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat Chem Biol (2015) 1.77
T-cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb Perspect Biol (2010) 1.45
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol (2014) 0.97
Identification of an allosteric signaling network within Tec family kinases. J Mol Biol (2010) 0.95
αC helix as a switch in the conformational transition of Src/CDK-like kinase domains. J Phys Chem B (2012) 0.93
Active site profiling reveals coupling between domains in SRC-family kinases. Nat Chem Biol (2012) 0.91
Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Sci (2011) 0.86
A hexylchloride-based catch-and-release system for chemical proteomic applications. ACS Chem Biol (2013) 0.82
Activation loop dynamics determine the different catalytic efficiencies of B cell- and T cell-specific tec kinases. Sci Signal (2013) 0.82
Divergent modulation of Src-family kinase regulatory interactions with ATP-competitive inhibitors. ACS Chem Biol (2014) 0.80
Novel Bruton's tyrosine kinase inhibitors currently in development. Onco Targets Ther (2013) 0.80
Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Comput Math Methods Med (2014) 0.79
Dynamic Allostery Mediated by a Conserved Tryptophan in the Tec Family Kinases. PLoS Comput Biol (2016) 0.79
A selective NMR probe to monitor the conformational transition from inactive to active kinase. ACS Chem Biol (2014) 0.78
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget (2016) 0.77
Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study. J Mol Graph Model (2015) 0.76
Specificity rendering 'hot-spots' for aurora kinase inhibitor design: the role of non-covalent interactions and conformational transitions. PLoS One (2014) 0.76
Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors. ChemMedChem (2016) 0.75
Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold. ACS Med Chem Lett (2016) 0.75
Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors. BMC Syst Biol (2017) 0.75
X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii. Ann Allergy Asthma Immunol (2013) 0.75
Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ. ACS Med Chem Lett (2016) 0.75
A specific and covalent JNK-1 ligand selected from an encoded self-assembling chemical library. Chemistry (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem (1989) 29.15
Searching protein structure databases with DaliLite v.3. Bioinformatics (2008) 12.15
An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr (2000) 7.78
The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature (1993) 7.39
Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell (1999) 5.09
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res (2006) 3.28
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem (2007) 2.96
The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure (2005) 2.78
Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 2.71
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat (2006) 1.55
Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function. J Biol Chem (1997) 1.43
Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem (1999) 1.35
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem (2009) 1.21
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem (2001) 1.18
Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering. EMBO J (2003) 1.13
Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors. J Biol Chem (2004) 1.02
Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett (2000) 0.98
Activation mechanism and steady state kinetics of Bruton's tyrosine kinase. J Biol Chem (2007) 0.95
Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families. Int Immunol (2005) 0.94
Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem (2006) 0.93
Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. J Biol Chem (2008) 0.93
The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem (2004) 0.90
Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity. Biochemistry (2009) 0.90
Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. Bioorg Med Chem Lett (2002) 0.89
X-linked agammaglobulinemia and Bruton's tyrosine kinase. Adv Exp Med Biol (1994) 0.82
Function of mitochondrial Stat3 in cellular respiration. Science (2009) 5.13
A common allosteric site and mechanism in caspases. Proc Natl Acad Sci U S A (2006) 2.12
Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol (2007) 2.07
Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe (2011) 1.86
Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A (2008) 1.81
The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two closely related homologues, StarD5 and StarD6. Proc Natl Acad Sci U S A (2002) 1.76
BLA to vHPC inputs modulate anxiety-related behaviors. Neuron (2013) 1.65
Interferon-beta reduces proteinuria in experimental glomerulonephritis. J Am Soc Nephrol (2007) 1.63
Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol (2005) 1.57
Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. Chem Biol (2004) 1.52
Religious attendance as a predictor of survival in the EPESE cohorts. Int J Epidemiol (2005) 1.52
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood (2011) 1.49
IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther (2008) 1.45
Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem (2006) 1.41
Role of nuclear factor-kappaB in the antiviral action of interferon and interferon-regulated gene expression. J Biol Chem (2004) 1.38
An allosteric circuit in caspase-1. J Mol Biol (2008) 1.38
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem (2006) 1.33
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol (2011) 1.33
Cross-generation and cross-laboratory predictions of Affymetrix microarrays by rank-based methods. J Biomed Inform (2007) 1.32
Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci (2007) 1.31
Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One (2010) 1.29
Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorg Med Chem Lett (2003) 1.27
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest (2003) 1.27
SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol (2008) 1.26
Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. J Mol Biol (2005) 1.25
Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J Biol Chem (2006) 1.23
Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun (2007) 1.21
The kinetic mechanism of phosphomevalonate kinase. J Biol Chem (2002) 1.19
Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A (2009) 1.17
Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett (2008) 1.15
Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration. J Biol Chem (2007) 1.14
Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol Cell Biol (2009) 1.13
Malonate-assisted purification of human caspases. Protein Expr Purif (2005) 1.12
Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun (2008) 1.11
Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol (2010) 1.10
Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J Biol Chem (2009) 1.09
Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorg Med Chem (2013) 1.07
Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc Natl Acad Sci U S A (2012) 1.03
Monitoring the transition from the T to the R state in E.coli aspartate transcarbamoylase by X-ray crystallography: crystal structures of the E50A mutant enzyme in four distinct allosteric states. J Mol Biol (2004) 1.01
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res (2006) 1.01
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors. Bioorg Med Chem Lett (2008) 1.00
Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One (2012) 1.00
Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif. J Biol Chem (2008) 0.99
Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood (2011) 0.98
Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol (2006) 0.95
Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1. PLoS Pathog (2011) 0.94
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol (2009) 0.93
Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering. Biochemistry (2009) 0.93
Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif (2004) 0.93
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a. J Pharmacol Exp Ther (2011) 0.92
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg Med Chem Lett (2011) 0.91
Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4. Bioorg Med Chem Lett (2006) 0.91
Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J Biol Chem (2011) 0.90
ROMPgel-supported triphenylphosphine with potential application in parallel synthesis. Org Lett (2002) 0.90
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem (2012) 0.90
Cells previously desensitized to type 1 interferons display different mechanisms of activation of stat-dependent gene expression from naïve cells. J Biol Chem (2003) 0.89
Parallel synthesis of terminal alkynes using a ROMPgel-supported ethyl 1-diazo-2-oxopropylphosphonate. Org Lett (2004) 0.88
Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands. Acta Crystallogr D Biol Crystallogr (2008) 0.88
Contrasting genome-wide distribution of 8-hydroxyguanine and acrolein-modified adenine during oxidative stress-induced renal carcinogenesis. Am J Pathol (2006) 0.88
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies. Proc Natl Acad Sci U S A (2012) 0.87
Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor. J Biol Chem (2011) 0.86
Interferon β induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice. Brain (2013) 0.86
Tethering identifies fragment that yields potent inhibitors of human caspase-1. Bioorg Med Chem Lett (2005) 0.86
Neurite outgrowth at the biomimetic interface. Ann Biomed Eng (2010) 0.84
Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem (2013) 0.84
Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture. Virol J (2012) 0.84
Increased cathepsin D release by Hyp mouse osteoblast cells. Am J Physiol Endocrinol Metab (2005) 0.84
2-Aminobenzimidazoles as potent Aurora kinase inhibitors. Bioorg Med Chem Lett (2009) 0.84
IRF7-dependent IFN-β production in response to RANKL promotes medullary thymic epithelial cell development. J Immunol (2013) 0.83
PEGylated interferon-beta modulates the acute inflammatory response and recovery when combined with forced exercise following cervical spinal contusion injury. Exp Neurol (2010) 0.83
Purifying the hedgehog protein and its variants. Methods Mol Biol (2007) 0.83
Bioconcentration and biotransformation of selenite versus selenate exposed periphyton and subsequent toxicity to the Mayfly Centroptilum triangulifer. Environ Sci Technol (2013) 0.82
Mouse Aurora A: expression in Escherichia coli and purification. Protein Expr Purif (2007) 0.81
An intermediate pH unfolding transition abrogates the ability of IgE to interact with its high affinity receptor FcepsilonRIalpha. J Biol Chem (2006) 0.81
Resolution of disulfide heterogeneity in Nogo receptor I fusion proteins by molecular engineering. Biotechnol Appl Biochem (2010) 0.81
Identification of individual protein-ligand NOEs in the limit of intermediate exchange. J Biomol NMR (2006) 0.80
Stage-specific roles of fibulin-5 during oxidative stress-induced renal carcinogenesis in rats. Free Radic Res (2010) 0.80
Structural analysis of caspase-1 inhibitors derived from Tethering. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.80
Type I interferons activate apoptosis in a Jurkat cell variant by caspase-dependent and independent mechanisms. Cell Signal (2005) 0.80
Interferon-β modulates type 1 immunity during influenza virus infection. Antiviral Res (2010) 0.80
Naturally occurring genetic variants of human caspase-1 differ considerably in structure and the ability to activate interleukin-1β. Hum Mutat (2012) 0.80
Sonic hedgehog signalling in neurons of adult ventrolateral nucleus tractus solitarius. Eur J Neurosci (2005) 0.80
Brain Dynamics in Predicting Driving Fatigue Using a Recurrent Self-Evolving Fuzzy Neural Network. IEEE Trans Neural Netw Learn Syst (2015) 0.79
Anti-inflammatory properties of Ajuga bracteosa in vivo and in vitro study and their effects on mouse model of liver fibrosis. J Ethnopharmacol (2011) 0.79
Disulfide structure of the leucine-rich repeat C-terminal cap and C-terminal stalk region of Nogo-66 receptor. Biochemistry (2005) 0.79
Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg Med Chem Lett (2008) 0.79
Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adult rats with acute Klebsiella pneumoniae meningitis. J Pineal Res (2010) 0.79
Deletion and single nucleotide substitution at G:C in the kidney of gpt delta transgenic mice after ferric nitrilotriacetate treatment. Cancer Sci (2006) 0.79
Protein N-acylation: H2O2-mediated covalent modification of protein by lipid peroxidation-derived saturated aldehydes. Chem Res Toxicol (2008) 0.78
Antagonism of chemokine receptor CCR8 is ineffective in a primate model of asthma. Thorax (2013) 0.78
Systemic administration of an Fcgamma-Fc(epsilon)-fusion protein in house dust mite sensitive nonhuman primates. Clin Immunol (2008) 0.78
Alpha-tocopherol induces calnexin in renal tubular cells: another protective mechanism against free radical-induced cellular damage. Arch Biochem Biophys (2006) 0.77
Host STAT2/type I interferon axis controls tumor growth. Int J Cancer (2014) 0.77
Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis. J Am Dent Assoc (2015) 0.77
Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors. Anticancer Res (2012) 0.77
Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.76